Packaging system for oxygen-sensitive drugs
AssigneeBecton Dickinson France
InventorsThomas Devouassoux, Eric Forat, James Kenneth Proctor
Life of this patent
Estimating the term…
Abstract
Described herein are pharmaceutical packaging systems which prevent oxidative degradation of morphine, hydromorphone, promethazine and other oxygen-sensitive drugs, such systems including a syringe with an oxygen permeable tip cap, a hermetically sealed oxygen barrier blister packaging with very low permeability to oxygen and comprises ethylene vinyl, and an oxygen absorber.
Claims17
A pharmaceutical packaging system for an injectable oxygen-sensitive drug, the packaging system comprising:
- (i) a syringe filled under inert conditions with an injectable oxygen-sensitive drug, wherein the syringe has an oxygen permeable tip cap and wherein the oxygen-sensitive drug is one of morphine, hydromorphone, and promethazine;
- (ii) a hermetically sealed oxygen barrier blister packaging which houses the syringe, wherein the blister packaging comprises a multilayer bottom web comprising ethylene vinyl alcohol (EVOH) and a multilayer top web lid comprising aluminum foil or EVOH;
- and
- (iii) an oxygen absorber, wherein the oxygen absorber reduces the oxygen level present from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.
A pharmaceutical packaging system for injectable morphine, the packaging system comprising:
- (i) a syringe filled under inert conditions with morphine, wherein the syringe has an oxygen permeable tip cap,
- (ii) a hermetically sealed oxygen barrier blister packaging which houses the syringe, wherein the blister packaging comprises a multilayer bottom web comprising ethylene vinyl alcohol (EVOH) and a multilayer top web lid comprising aluminum foil or EVOH;
- and
- (iii) an oxygen absorber, wherein the oxygen absorber reduces the oxygen level from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.
A pharmaceutical packaging system for injectable hydromorphone, the packaging system comprising:
- (i) a syringe filled under inert conditions with hydromorphone, wherein the syringe has an oxygen permeable tip cap,
- (ii) a hermetically sealed oxygen barrier blister packaging which houses the syringe, wherein the blister packaging comprises a multilayer bottom web comprising ethylene vinyl alcohol (EVOH) and a multilayer top web lid comprising aluminum foil or EVOH;
- and
- (iii) an oxygen absorber, wherein the oxygen absorber reduces the oxygen level from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.
A pharmaceutical packaging system for injectable promethazine, the packaging system comprising:
- (i) a syringe filled under inert conditions with promethazine, wherein the syringe has an oxygen permeable tip cap,
- (ii) a hermetically sealed oxygen barrier blister packaging which houses the syringe, wherein the blister packaging comprises a multilayer bottom web comprising ethylene vinyl alcohol (EVOH) and a multilayer top web lid comprising aluminum foil or EVOH;
- and
- (iii) an oxygen absorber, wherein the oxygen absorber reduces the oxygen level from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.
Dependencies are inferred from the claim text.